Size : | Price | Quantity | |
---|---|---|---|
10 mg | $35.00 | ||
100 mg | $75.00 |
Erlotinib HCl (182219-93-9) is a potent inhibitor of EGFR tyrosine kinase (IC50 = 2 nM).1 Potent inhibitor of mutant JAK2-V617F.2 Weaker inhibitor of ErbB-2 kinase (Ki = 1 μM) ErbB-4 kinase (Ki = 1.5 μM).3 HDAC inhibitors sensitize for erlotinib activity in EGFR-mutated and wildtype non-small cell lung cancer (NSCLC) cells.4 A clinically effective agent for NSCLC.5
References/Citations:
1) Moyer et al. (1997), Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor tyrosine kinases; Cancer Res., 57 4838
2) Li et al. (2007), Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth; J. Biol. Chem., 282 3428
3) Wood et al. (2004), A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells; Cancer Res., 64 6652
4) Greve et al. (2015), The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and –wildtype non-small cell lung cancer cells; BMC Cancer, 15 947
5) Minquet et al. (2016), Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives; Int. J. Cancer, 138 2549
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Erlotinib HCl (182219-93-9) is a potent inhibitor of EGFR tyrosine kinase (IC50 = 2 nM).1 Potent inhibitor of mutant JAK2-V617F.2 Weaker inhibitor of ErbB-2 kinase (Ki = 1 μM) ErbB-4 kinase (Ki = 1.5 μM).3 HDAC inhibitors sensitize for erlotinib activity in EGFR-mutated and wildtype non-small cell lung cancer (NSCLC) cells.4 A clinically effective agent for NSCLC.5
References/Citations:
1) Moyer et al. (1997), Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor tyrosine kinases; Cancer Res., 57 4838
2) Li et al. (2007), Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth; J. Biol. Chem., 282 3428
3) Wood et al. (2004), A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells; Cancer Res., 64 6652
4) Greve et al. (2015), The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and –wildtype non-small cell lung cancer cells; BMC Cancer, 15 947
5) Minquet et al. (2016), Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives; Int. J. Cancer, 138 2549
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.